---
title: "HUGHES OWEN — Ownership Dossier"
canonical: https://whiteintel.dev/entity/46795809-62fd-5321-b993-ee5fdcfc11fa
json: https://whiteintel.dev/api/public/dossier/46795809-62fd-5321-b993-ee5fdcfc11fa
identifier: sec:0001575933
jurisdiction: US
risk: Low
source: WhiteIntel corporate-ownership graph
---

# HUGHES OWEN

**Type:** Company  
**Jurisdiction:** US  
**Identifier:** `sec:0001575933`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/46795809-62fd-5321-b993-ee5fdcfc11fa  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/46795809-62fd-5321-b993-ee5fdcfc11fa  

## Ownership & control

### Holdings / subsidiaries

- **C4 Therapeutics, Inc.** (director) — https://whiteintel.dev/entity/e7ae52ea-8765-54cb-a228-2de27cbc8bbd
- **XOMA Royalty Corp** (officer) — https://whiteintel.dev/entity/879bcb76-24e5-5154-a262-697323c83673
- **XOMA Royalty Corp** (director) — https://whiteintel.dev/entity/879bcb76-24e5-5154-a262-697323c83673
- **ANAPTYSBIO, INC** (director) — https://whiteintel.dev/entity/d5e7f599-7eb4-5864-8e4a-7194dc20c2de
- **IKENA ONCOLOGY, INC.** (director) — https://whiteintel.dev/entity/f9029479-562f-556f-b3f1-0280f03ade9d
- **MPM ACQUISITION CORP** (director) — https://whiteintel.dev/entity/6ba1394a-97c0-5b9d-9529-b52f63e198b8
- **FS DEVELOPMENT CORP. II** (director) — https://whiteintel.dev/entity/d3d96da3-e733-5a65-aa9f-e7f0254d7d01
- **RANA THERAPEUTICS, INC.** (director) — https://whiteintel.dev/entity/50c4ec42-16e1-5564-bebf-39fd813de0d8
- **Cullinan Therapeutics, Inc.** (officer) — https://whiteintel.dev/entity/e103e223-6420-5795-bce5-450261fac1da
- **Cullinan Therapeutics, Inc.** (director) — https://whiteintel.dev/entity/e103e223-6420-5795-bce5-450261fac1da

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **HUGHES OWEN**. Human view: https://whiteintel.dev/entity/46795809-62fd-5321-b993-ee5fdcfc11fa · Structured JSON: https://whiteintel.dev/api/public/dossier/46795809-62fd-5321-b993-ee5fdcfc11fa._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._